Pfizer Inc
NYSE: PFE
$29.67
+$0.23 (+0.8%)
Closing Price on October 16, 2024
PFE Articles
According to Reuters, Yahoo! (YHOO) rejected a tie up with Google (GOOG) before the Microsoft (MSFT) bid. Retuers writes that loses may force Lehman (LEH) to raise another $3.4 billion. Reuters...
Published:
GM (GM) falls as sales appear to falter. Down to $16.87 from 52-week high of $43.20. The Colonial BancGroup (CNB) Worries about bank failures push shares down to $5.65 from 52-week high of $25.50....
Published:
It looks like Pfizer’s (PFE) anti-smoking drug Chantix makes people kick the habit but at the same time can push them toward suicide or depression. It is a hard decision whether patients want to...
Published:
According to Reuters, the Fed lower growth expectations and noted rising inflation. Reuters writes that AMR (AMR) will sharply cut the number of routes its serves and take certain planes out of...
Published:
Last night was a novel release from the American Society of Clinical Oncology (or ASCO) as the society decided to publish all of the findings to the public at once. Keep in mind that many of the...
Published:
Last Updated:
The mid-month reports on short interest in NYSE shares showed that many short sellers moved out of big financial stocks but made large bets against airlines and auto companies. With the prices in...
Published:
National City Corporation (NCC) Raising money and big dilution. Falls to $5.90 from 52-week high of $38.32. Pfizer (PFE) Concerns about big pharma results. Drifts off to $20.13. $27.73. Aladdin...
Published:
Pfizer, Inc (NYSE: PFE) has signed an agreement with the much smaller AVANT Immunotherapeutics (NASDAQ: AVAN). The two have announced an agreement where Pfizer will be granted an exclusive...
Published:
Last Updated:
Medarex, Inc. (NASDAQ: MEDX) wants to clarify a few issues regarding the study halt from Pfizer (NYSE: PFE) this week on advanced melanoma. The company says that there are key differences between...
Published:
Medarex Inc. (NASDAQ: MEDX) Saw shares plummet in pre-market trading. Pfizer Inc. (NYSE: PFE) has ended a Phase III clinical trial of tremelimumab in patients with advanced melanoma after a review...
Published:
Last Updated:
Those rummaging through the garbage of 52-week low lists are usually bottom-fishing investors or desperate CEOs. But, the list is so broad that it has become a tableau of the market as a whole,...
Published:
This was a massive list of lows today. Not all closed on lows, but the list was chopped down greatly just to accommodate the size of it. If you look at the list, there are no brokerage firms...
Published:
CyDex Pharmaceuticals, Inc. has filed to come public via an IPO in what it lists for filing purposes as up to $50 million in securities sales. It has applied to have the common stock approved for...
Published:
Pfizer Inc. (NYSE: PFE) has given some of its basic data points for its analyst meeting today. For starters, the company has reaffirmed its guidance for 2008 that it previously offered. That...
Published:
Last Updated:
These are not the only analyst calls affecting shares of stock this morning, but these are the initial calls that a673b.bigscoots-temp.com is focusing on: AIG (NYSE: AIG) cut to Market Perform at KBW....
Published: